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Proteasome inhibition has emerged as a powerful option for the treatment of a number of malig-
nancies including leukemias. However, Bortezomib showed limited single-agent activity for patients
with leukemia. Here, we report for the ﬁrst time that Bortezomib up-regulated a novel antiapoptotic
protein, BAG3, in human leukemic cells. BAG3 gene knockdown with shRNA greatly potentiated the
generation of apoptosis by Bortezomib in leukemia cells. Furthermore, BAG3 silencing enhanced the
antitumor activity of Bortezomib dramatically in a nude mouse model. Our results indicate that
knocking down BAG3 gene is a promising new approach to enhance the therapeutic potency of Bort-
ezomib in leukemia.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The proteasome is a multisubunit proteolytic complex that is
responsible for the degradation of 80% of all cellular proteins. It
also plays a central role in normal cell cycling, function, and
survival by mediating the degradation of ubiquitylated target
proteins, making proteasome inhibition a novel therapeutic target
in cancer [1–4]. Bortezomib was the ﬁrst proteasome inhibitor
used in clinical trials and has been approved for the treatment of
patients with refractory multiple myeloma. Studies indicated that
Bortezomib exerts its antitumor activity through stabilizing p21,
p27 and p53, as well as the pro-apoptotic Bid and Bax proteins,
caveolin-1 and NF-jB inhibitor IjB-a [5,6]. Based on the solid pre-
clinical rationale, Bortezomib was introduced into a number of
clinical trials for a broader spectrum of diseases including leuke-
mias [6,7]. However, the pleiotropic effects of proteasome inhibi-
tors also result in activation of antiapoptotic pathways that may
compromise their antitumor activity. This phenomenon may par-
tially explain the limited single-agent activity of Bortezomib in pa-
tients with leukemia. These ‘‘unwanted” pathway mediators
mentioned above include heat shock response proteins (HSPs),
mitogen-activated protein kinase phosphatase-1 and protein ki-
nase B/Akt [6,8].
BAG3 is a member of the cochaperone family which contains
the BAG (Bcl-2-Associated Athanogene) domain and is character-
ized by its property of biochemically and functionally interacting
with a variety of partners, including HSPs, steroid hormone recep-chemical Societies. Published by E
).tors, Bcl-2, Raf-1, involved in modulating cell proliferation and
apoptosis [9–14]. Several studies showed that, in human primary
lymphoid and myeloblastic leukemias and other neoplastic cell
types, BAG3 expression sustains cell survival and underlies resis-
tance to therapy, through downmodulation of apoptosis [15–17].
Here, we report for the ﬁrst time that Bortezomib upregulated
BAG3 expression in leukemic cells and that BAG3 gene silencing
greatly potentiates the apoptotic action of this drug.2. Materials and methods
2.1. Cell culture and reagents
HL-60, U937, Jurkat, and MO7-e human leukemia cell lines were
purchased from American Type Culture Collection (Rockville, MD).
All cells were routinely grown in suspension in RPMI 1640 medium
(Gibco, Grand Island, NY) containing glutamine (0.200 g/L), antibi-
otics (penicillin 100 IU/mL; streptomycin 100 lg/mL) and supple-
mented with 10% heat-inactivated fetal bovine serum (FBS), in a
5% CO2 humidiﬁed atmosphere at 37 C. Cell viability was deter-
mined by using a trypan blue dye exclusion assay. Bortezomib is
commercially available from Millennium Pharmaceuticals
(Cambridge, MA).
2.2. Western blot
Whole-cell pellets were lysed in 50 mM Tris–HCl (pH 7.6) buffer
containing 0.15 M NaCl, 1 mM EDTA, 10 lg/mL leupeptin andlsevier B.V. All rights reserved.
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sates were resolved by SDS–PAGE and transferred to nitrocellulose
membranes (Bio-Rad). Membranes were blocked in bovine serum
albumin (3%) in Tris-buffered saline (TBS)–Tween 20 (0.05%) and
incubated with antibodies against human BAG3 (Alexis Biochemi-
cals, San Diego, CA), p21 (Calbiochem, La Jolla, CA), bcl-2, IjB-a and
Phospho-IjB-a (Cell Signaling, Beverly, MA) at 1:1000 dilutions fol-
lowed by horseradish peroxidase–conjugated secondary antibodies
at 1:5000 dilutions. Detection was performed by using enhanced
chemiluminescence (ECL).
2.3. 20S proteasome activity assay
Cytosolic extracts (without protease inhibitors) were used to
measure proteasome activity using 20S proteasome assay kit
(Chemicon International, Temecula, CA) following the manufac-
turer’s instructions. The assay is based on detection of the ﬂuoro-
phore 7-amino-4-methylcoumarin (AMC) after cleavage from the
labeled substrate LLVY-AMC. The free AMC ﬂuorescence was quan-
tiﬁed using a 380/460-nm ﬁlter set in a ﬂuorometer.
2.4. Assessment of apoptosis
After drug exposure, cells were washed with 1 PBS and stained
with annexin V/PI (BD Pharmingen) for 30 min at room tempera-
ture. Cells were then processed and analyzed using a Becton Dick-
inson FACScan cytoﬂuorometer (Mansﬁeld, MA) with the use ofFig. 1. Bortezomib up-regulates BAG3 expression in human leukemia cell lines. (A and B)
the indicated time, after which proteasome activity was analyzed as described in Sectio
U937 cell lines were incubated in 10 nM Bortezomib for the indicated time. Total protein
probed for p21 and pIjB to conﬁrm proteasome activity inhibition. IjB protein was also d
and MO7-e cells were treated with 10 nM Bortezomib for 16 h. Western blot was then p
anti-a-tubulin antibody to show equal loading of total protein.Cell Quest software (Becton Dickinson, Palo Alto, CA). Cells were
considered to be apoptotic if they were either annexin V+/PI
(early apoptotic) or annexin V+/PI+ (late apoptotic).
2.5. Caspase-3. activity
Caspase-3 activity was measured on cell extract by a colorimet-
ric procedure using the speciﬁc peptide substrate DEVD-pNa as de-
scribed previously [18]. Brieﬂy, Cells (2  106) were pelleted,
washed with PBS, and lysed in 50 mM Tris–HC1, pH 7.5, 0.03%
NP-40, 1.0 mM DTT. Lysates were centrifuged at 14000 rpm for
15 min at 4 C. Total protein determination was done using the
Bradford assay. Assays were set up in 96 well plates containing
0.2 mM DEVD-pNa in a caspase reaction buffer (100 mM HEPES,
pH 7.5, 10% sucrose, 0.1% CHAPS, 10 mM DTT) and 0.01 ml of pro-
tein extract (20–50 lg) in a total volume of 0.1 ml. Assays were
incubated at 37 C. Release of pNa was detected by periodic read-
ings of absorbance at 405 nm taken against a blank containing buf-
fer and peptide alone (i.e., no extract) from 0 to 5 h to mark the
linearity of the enzymatic reaction in time. Enzyme activities were
measured as initial velocities and expressed as relative intensity/
min/mg total protein within the linear range of the response.
2.6. shRNAs
Short-hairpin RNAs (shRNAs) cloned into the vector pLKO.1-
puro were chosen from the human library (MISSION TRC-Hs 1.0)Human leukemic HL-60 and U937 cell lines were incubated in 10 nM Bortezomib for
n 2. Results are shown as means ± S.D. of triplicates samples. (C and D) HL-60 and
extracts from both cell lines were analyzed by Western blotting. Membranes were
etected. a-Tubulin was probed as an equal loading control. (E) HL-60, U937, Jurkat,
erformed to detect BAG3 protein levels. The blot was stripped and re-probed with
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man BAG3 gene used in this study were shBAG3-1 plasmid,
CCGGGCATGCATTTCAGAGACTTTACTCGAGTAAAGTCTCTGAAATGC-
ATGCTTTTT and shBAG3-2, CCGGCTTGAACAGAAAGCCATTGATCTC-
GAGATCAATGGCTTTCTGTTCAAGTTTTT, respectively. The control
shRNA (non-target shRNA vector, Sigma) contains a hairpin insert
that will generate siRNAs but contains ﬁve base pair mismatches
to any known human gene. Pooled stable transfectants were estab-
lished using puromycin selection (2 lg/mL).
2.7. Mice
Female immune deﬁcient BALB/c nude mice at 4 weeks of age
were maintained in pathogen-free conditions with irradiated
chow. Animals were bilaterally, s.c. injected with 2  106 HL-60
transfects stably expressing control shRNA or shBAG3-2 in 0.1 ml
Matrigel (Collaborative Biomedical Products, Bedford, MA, USA),
forming two tumors/mouse. When HL-60 tumors were palpable,
mice were randomized into six groups (n = 5) and were treated
intraperitoneally with Bortezomib at 1 mg/kg twice a week or with
vehicle only. The subcutaneous tumors were measured twice a
week and tumor sizes were calculated by the formula: a  b  c,
where ‘a’ is the length and ‘b’ is the width and ‘c’ is the height in
millimeters. At the end of the experiment, animals were killed by
CO2 asphyxiation and tumor weights were measured after careful
resection.
2.8. Statistical analysis
Data are presented as means ± S.D. of at least three independent
experiments. Differences between groups were analyzed usingFig. 2. BAG3 gene knockdown sensitizes leukemic cells to Bortezomib-induced apoptosis
1/-2 were exposed to 10 nM Bortezomib for 16 h, after which BAG3 protein level was
expressing control shRNA or shBAG3-1/-2 were exposed to 10 nM Bortezomib for 16
cytometry. Results are shown as means ± S.D. of triplicates samples. *P < 0.05, **P < 0.01.two-tailed Student’s t-test. P < 0.05 was considered statistically
signiﬁcant.3. Results and discussion
It has been showed that Bortezomib inhibits the 26S protea-
some by binding the chymotrypsin-like active site in the 20S core
complex. We ﬁrst conﬁrmed the proteasome inhibitory activity of
this drug at concentration used in this study. Human leukemic HL-
60 and U937 cell lines were incubated in 10 nM Bortezomib for up
to 16 h, after which proteasome activity was analyzed as described
in Section 2. As shown in Fig. 1A and B, exposure to 10 nM Bortezo-
mib for 4 or more hours resulted in approximately 80% and 70%
reduction in proteasome activity in HL-60 and U937 cells, respec-
tively. To further validate the assay, the levels of several proteins
known to be regulated by proteasome were detected after Bortezo-
mib incubation. Fig. 1C and D shows the accumulation of p21, and
the phosphorylated form of IjB after 10 nM Bortezomib incubation
for the indicated time in both cell lines tested. However, there was
a slight decrease in the amount of IjB following Bortezomib treat-
ment, which is consistent with previous report [19]. We then
checked the effect of Bortezomib treatment on BAG3 expression
in leukemic cell lines. HL-60, U937, Jurkat, and MO7-e cell lines
were incubated in 10 nM Bortezomib for 16 h and BAG3 level
was measured by Western blot. As shown in Fig. 1E, Bortezomib
markedly up-regulated BAG3 expression at protein level in all
these four cell lines.
To evaluate the potential role of BAG3 in Bortezomib-induced
apoptosis, we used two shRNA-expressing plasmids with different
target sequences to induce BAG3 gene silencing and established. (A) HL-60 and U937 stable transfectant cells expressing control shRNA or shBAG3-
analyzed by Western blot analysis. (B) HL-60 and U937 stable transfectant cells
h, after which apoptotic cells were monitored by annexin V/PI staining and ﬂow
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cell lines. BAG3 gene knockdown with shRNA was conﬁrmed by
immunoblot as shown in Fig. 2A. As shown in Fig. 2B, BAG3 gene
down-regulation greatly potentiated the generation of apoptosis
by Bortezomib, with higher efﬁcacy in the case of HL-60 cells, re-
ﬂected by annexin V/PI staining. Moreover, BAG3 gene silencing
markedly enhanced caspase-3 activation caused by Bortezomib
treatment (Fig. 3A). However, little change was noted in the
expression of Bcl-2 protein in cells treated with Bortezomib or
shRNA targeting BAG3 (Fig. 3B). We further determine the effect
of modulating BAG3 expression on the anticancer activity of Bort-
ezomib in vivo. A nude mouse model was generated using HL-60
stable transfectants expressing shBAG3-2, which had higher efﬁ-
cacy of BAG3 knockdown than the other transfectant shBAG3-1
in HL-60 cells, as determined in Fig. 2A. When HL-60 tumors were
palpable, mice were randomized into six groups (n = 5) and were
treated intraperitoneally with Bortezomib at 1 mg/kg twice a
week, a safe and moderate dose suggested by previous studies
[20–23]. As shown in Fig. 4A and B, although BAG3 silencing alone
had no inﬂuence on leukemic cell growth in vivo, it enhanced the
antitumor activity of Bortezomib dramatically, resulting in de-
creased tumor growth and weight at autopsy.
The 26S ubiquitin–proteasome, formed by the 20S core complex
and the 19S regulatory particle, is present in both the cytoplasm
and the nucleus of all eukaryotic cells and modulates both the
levels and functions of many proteins involved in cell cycle pro-
gression, differentiation, apoptosis, and adhesion to the microenvi-
ronment [24–29]. With the approval of the proteasome inhibitor
Bortezomib for clinical use, proteasome inhibition has emerged
as a powerful option for the pharmacological treatment of multipleFig. 3. Effect of BAG3 gene silencing on caspase-3 activity and bcl-2 expression. (A) HL-6
exposed to 10 nM Bortezomib for 16 h, after which caspase-3 activity was determined in
as described in Section 2. OD indicates optical density. (B) HL-60 and U937 stable tra
Bortezomib for 16 h, after which Bcl-2 protein level was analyzed by Western blot analmyeloma and possibly other malignancies including leukemias.
However, despite encouraging preclinical data, Bortezomib
showed limited single-agent activity for patients with leukemia,
which is as yet unexplained. It is interesting to note that Bortezo-
mib may also inhibit the degradation of antiapoptotic pathway
mediators and thereby suppress the antitumor activity of its
own. Thus, these antiapoptotic molecules could be targets for
chemosensitization to proteasome inhibitors [6].
BAG-family proteins represent an evolutionarily conserved
group of HSP70/HSC70-binding co-chaperones, with six members
identiﬁed in the human and mouse genomes. HSP70/HSC70 family
proteins regulate a variety of cellular processes, including signal
transduction, transcription, and protein degradation [13,14,30].
BAG3 binds to the ATPase domain of HSC70 with high afﬁnity
and thereby inhibits its chaperone activity [14,31]. In a mouse
model, BAG3 gene deﬁciency resulted in fulminant myopathy
and an early lethality [32]. Moreover, BAG3 prevents cell death
through synergizing with Bcl-2 [11]. It has been found to down-
modulate the apoptotic response to tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) in thyroid carcinomas [33]. In
addition, an antiapoptotic role of this gene was reported in chronic
lymphocytic leukemia and acute lymphoblastic leukemia primary
cultures [15–17]. BAG3 has been demonstrated to be induced by
proteasome inhibitor MG132 in various cancer cells at the tran-
scriptional level [34]. A more recent report showed that Bortezo-
mib-induced BAG3 mRNA and protein expression in proximal
tubular epithelial cells [35]. However, little is known about the role
of BAG3 in Bortezomib-induced apoptosis.
Evidence is emerging which suggests a beneﬁcial role of
Bortezomib in leukemia protocols. Our results from both in vitro0 and U937 stable transfectant cells expressing control shRNA or shBAG3-1/-2 were
cell extracts by means of a colorimetric assay of the DEVD-pNa substrate hydrolysis
nsfectant cells expressing control shRNA or shBAG3-1/-2 were exposed to 10 nM
ysis.
Fig. 4. Effect of modulating BAG3 expression on the antiproliferative activity of Bortezomib in vivo. (A) Female immune deﬁcient BALB/c nude mice at 4 weeks of age were
bilaterally, s.c. injected with 2  106 HL-60 transfects stably expressing control shRNA or shBAG3-2, forming two tumors/mouse. When HL-60 tumors were palpable, mice
were randomized into six groups (n = 5) and were treated intraperitoneally with Bortezomib (Bort) at 1 mg/kg twice a week or with vehicle only. The subcutaneous tumors
were measured twice a week and tumor sizes were calculated by the formula: a  b  c, where ‘a’ is the length and ‘b’ is the width and ‘c’ is the height in millimeters. Each
point represents the means ± S.D. of 10 tumors. (B) Relative Tumor weights at autopsy. After 2 weeks of treatment, tumors were removed and weighed. The weight of parental
HL-60 tumors treated with vehicle only is set as 100%. Results represent means ± S.D. of tumor weights. Asterisks are given for signiﬁcances of shBAG3 versus control shRNA
in Bortezomib-treated groups. *P < 0.05, **P < 0.01.
P. Liu et al. / FEBS Letters 583 (2009) 401–406 405apoptosis assay and in vivo animal model indicate that knocking
down BAG3 gene is a promising new approach to enhance the ther-
apeutic potency of Bortezomib in patients with leukemia.
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